RedDress announced the launch of ActiGraft as the first wound care treatment that enables healthcare providers to produce – in real time – a patient’s blood into an autologous whole blood clot tissue to heal wounds and ulcers. The product was recently granted 510(k) marketing clearance by the Food and Drug Administration.
ActiGraft can be used for the management of a variety of chronic and acute wounds, including diabetic foot ulcers, pressure ulcers, leg ulcers, skin tears, and mechanically or surgically-debrided wounds. The Company’s proprietary technology uses a 15mL sample of the patient’s blood mixed with an autologous graft wound care solution to produce the whole blood clot in 12 minutes. Once applied, ActiGraft contains a provisional extracellular matrix that serves as the protective covering, biologic fibrin scaffold, and wound microenvironment to promote natural wound healing processes.
According to RedDress, the benefits of ActiGraft include significantly faster healing with less wound interaction and pain, as well as weekly vs daily application; the period between applications can be prolonged as wound healing progresses.
“There’s an estimated 6.5 million people in the US suffering from severe, debilitating wounds and ulcers; the development of a treatment that replicates one’s own natural healing process was our solution to address the community’s unmet need and transform the way healthcare providers, patients, and their caregivers, manage hard-to-treat wounds and ulcers,” said Alon Kushnir, Founder and CEO of RedDress.
The ActiGraft kit contains all sterile tools and materials, including: blood draw equipment, coagulation tools and materials, primary and secondary dressing equipment, procedure tray and sterile sheet.
For more information visit reddressmedical.com.
This article originally appeared on MPR